Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MKC-1

An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites… Expand
National Institutes of Health

Related topics

Related topics

2 relations
Microtubule ProcessR440

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer
Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding-protein (PEBP) family that modulates the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
SummaryBackground MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin… Expand
  • table 1
  • figure 1
  • figure 2
  • table 3
  • table 2
2010
2010
The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent.
Bisindolylmaleimide MKC-1 (formerly known as Ro 31-7453) is a novel, orally active, small-molecule, cell cycle inhibitor with… Expand
2010
2010
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
SummaryBackground MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2009
2009
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.
  • C. Elser, H. Hirte, +7 authors A. Oza
  • Journal of clinical oncology : official journal…
  • 2009
    • Corpus ID: 12301460
5577 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity in xenograft models of human ovarian and… Expand
2009
2009
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi… Expand
2008
2008
A phase II study of oral MKC-1 for metastatic breast cancer (MBC)
1046 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines… Expand
2007
2007
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity… Expand
2007
2007
MKC-1 significantly increases survival of mice bearing renal cell carcinoma Caki-1 xenograft tumors through inhibition of the Akt/mTOR pathway
B290 MKC-1 (previously Ro 31-7453) is a novel, orally active cell cycle inhibitor with significant in vitro and in vivo activity… Expand
1999
1999
In vitro characteristics of early epidermal progenitors isolated from keratin 14 (K14)‐deficient mice: Insights into the role of keratin 17 in mouse keratinocytes
Keratin 14 (K14) is believed to play a pivotal role in the maintenance of epidermal cell shape and contributing to their… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE